Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Palantir Technologies Inc (PLTR) vs Viatris Inc (VTRS) Price & Performance

Palantir Technologies IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Palantir Technologies Inc vs Viatris Inc — how do they compare? Palantir Technologies Inc trades at $169.1 (market cap $409.24B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Palantir Technologies Inc is far larger — about 21.4× Viatris Inc's market cap, and Viatris Inc pays a 2.89% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.

PLTRVTRS
Market Cap
$409.24B$19.09B
Sector
TechnologyHealth
52-Week High
$207.18$17.86
52-Week Low
$107.27$9.49
Enterprise Value
$400.04B$31.21B
Dividend Yield
2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Palantir Technologies Inc

Palantir (PLTR) trades at $170.30, down 2.31% on the day, with technical indicators showing neutral signals amid strong fundamental performance. The company reported exceptional Q2 2026 results with EPS of $0.41 beating expectations by 19%, while revenue growth accelerated to 93% year-over-year. Recent news highlights the strategic Nebius partnership for sovereign AI infrastructure, positioning Palantir to address growing enterprise demand for private AI deployment solutions.

While valuation metrics remain elevated with P/E of 145.6 and P/S of 71.1, the company's 49% net margin and 38.4% ROE demonstrate strong profitability. The consensus price target of $211.38 suggests 24% upside potential, though competitive pressures and high expectations create execution risks. Investors face the tension between premium valuation and exceptional growth trajectory.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Palantir Technologies Inc

Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.

Read more on PLTR

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS